Copyright
©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 983-999
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.983
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.983
Table 2 Ongoing clinical trials of radiotherapy and immune checkpoint inhibitors combination in locally advanced stage non-small-cell lung cancer in the neoadjuvant setting
Ref. | Phase | Design | No.ofpatients | Tumor stage | RT | ICI agent | Sequence | Status |
CASE4516, NCT02987998[72] | 1 | Neoadjuvant CRT (CDDP-etoposide) + ICI followed by surgery and consolidative ICI | 20 | Resectable IIIA | 45 Gy/25 fx (1.8 Gy/fx) | Pembroli zumab | Concomitant (neoadjuvant) + adjuvant ICI | Active, not recruiting |
NCT03237377[73] | 2 | Neoadjuvant RT-ICI followed by surgery +/-adjuvant CT | 32 | Resectable IIIA | 45 Gy/25 fx (1.8-2 Gy/fx) | Durvalumab ± tremelimumab | Concomitant(neoadjuvant) | Recruiting |
NCT04245514, SAKK 16/18[74] | 2 3 RT arms | Neoadjuvant RT-ICI followed by surgery | 90 | Resectable IIIA | Randomized 1:1:1; A: 20 × 2 Gy; B: 5 × 5 Gy; C: 3 × 8 Gy (non -consecutive days) | Durvalumab | Concomitant (neoadjuvant) | Recruiting |
INCREASE, NL8435[75] | 2 single arm | Neoadjuvant CRT (platinum doublet) + ICI followed by surgery | 29 | Resectable IIB-III (T3-4 N0-1) | 50 Gy/25 fx | Ipilimumab + Nivolumab | Concomitant (neoadjuvant) | Recruiting |
NCT02904954[76] | 2 randomized | Neoadjuvant ICI +/- SBRT followed by surgery and adjuvant maintenance ICI | 60 | Resectable I-IIIA | SBRT 24 Gy/3 fx | Durvalumab | Concomitantneoadjuvant + adjuvant ICI | Active, not recruiting |
NCT03871153[77] | 2 single arm | Neoadjuvant CRT (Carbo-taxol) + ICI followed by surgery and adjuvant ICI | 25 | Resectable IIIA N2 | 45-61.2 Gy (25-34 fx a 1.8-2 Gy/fx) | Durvalumab | Concomitant (neoadjuvant) + adjuvant ICI | Recruiting |
CHIO3, NCT04062708[78] | 2single arm | Concomitant neoadjuvant CT (platinum doublet + ICI followed by surgery + adjuvant RT followed by ICI | 55 | Resectable IIIA-IIIB | 54 Gy | Durvalumab | Concomitant CT-ICI (neoadjuvant) + adjuvant ICI (after adjuvant RT) | Not yet recruiting |
NCT03102242[79] | 2singlearm | Induction ICI followed by definitive CRT (Carbo-Taxol followed by consolidation CT-ICI | 63 | Unresectable IIIA-IIIB | 60 Gy/30 fx | Atezolizumab | Neoadjuvant + consolidative ICI | Active, notrecruiting |
NCT02572843[80] | 2 | Neoadjuvant CT (platinum + docetaxel) + ICI followed by surgery +/-RT + ICI | 68 | Resectable IIIA N2 | Convenional RT if R1-R2 and before adjuvant ICI | Durvalumab | Neoadjuvant + adjuvant | Active, not recruiting |
- Citation: Luna J, Zafra J, Areses Manrique MC, Rodríguez A, Sotoca A, Fírvida JL, Chicas-Sett R, Mielgo X, Reyes JCT, Couñago F. New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World J Clin Oncol 2021; 12(11): 983-999
- URL: https://www.wjgnet.com/2218-4333/full/v12/i11/983.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i11.983